RxDoctor Payments Data

Babak Yasmeh, MD

Clinical Cardiac Electrophysiology · Corona, CANPI 1417392622

Payments from drug & device makers

$71,334in general payments, 2019–2025

Across 282 payments — averaging $252.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$39K
  • Biotronik Inc.$12K
  • Medtronic$11K
  • Boston Scientific$7K
  • Biosense Webster, Inc.$1K
  • Medical Device Business Services, Inc.$573
  • plus $596 from 11 others

What the payments were for

  • Consulting fees$8,35014%
  • Grants$21,03235%
  • Travel & lodging$19,68733%
  • Food & beverage$10,29617%
  • Education$740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,334 in reported general payments places this provider in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$42,116
Medicare patients
228
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$354,224
XareltoRivaroxaban32$34,903
Dofetilide55$7,701
Metoprolol Succinate231$4,390
Amiodarone Hcl170$3,826
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,632
Flecainide Acetate28$786
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$449
Digoxin16$367
SotalolSotalol Hcl14$206
Metoprolol Tartrate21$151
Carvedilol11$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$354,224339 claims
Johnson & JohnsonXarelto$17$34,90332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →